Company

Bank

Analyst

Coverage

Opinion

Wk chg

9/6 cls

Pharmacyclics Inc. (NASDAQ:PCYC)

Lazard

Joshua Schimmer

Upgrade

Buy (from neutral)

6%

$117.74

Schimmer also set a $141 target after a handful of community hematology and oncology specialists said ibrutinib could reach over $5B in global sales "far faster than the 2020 modeled by consensus." He expects 2020 worldwide sales at $3B-$11B. An NDA for the Bruton's tyrosine kinase (Btk) inhibitor to treat relapse or refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL) is under Priority Review in the U.S. with a Feb. 28, 2014, PDUFA date.